Top Markets
#1 Electroneum Electroneum +19.24%
#2 Status Status +17.72%
#3 Thena Thena +12.24%
#4 Infinity Ground Infinity Ground +9.61%
#5 Ski Mask Dog Ski Mask Dog +8.58%
#6 TG.Casino TG.Casino +6.03%
#7 Bitway Bitway +4.96%
#8 City Boy City Boy +4.93%
#9 Hex Trust USD Hex Trust USD +4.55%
#10 The Grays Currency The Grays Currency +4.30%
Coin of the day
Electroneum Electroneum
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Kedudukan dalam Saham #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Harga Saham
$451.59
Modal Pasaran
$114.70B
Perubahan (1 hari)
-2.36%
Perubahan (1 tahun)
-11.89%
Negara
US
Perdagangan Vertex Pharmaceuticals Incorporated (VRTX)

Kategori

Healthcare
Nisbah P/E bagi Vertex Pharmaceuticals Incorporated (VRTX)
Nisbah P/E pada March 2026 TTM: 30.14
Menurut laporan kewangan dan harga saham terkini Vertex Pharmaceuticals Incorporated, nisbah P/E semasa (TTM) ialah 30.14. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak 28.97.
Sejarah nisbah P/E bagi Vertex Pharmaceuticals Incorporated dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 30.14 -115.57%
2024 -193.61 -768.33%
2023 28.97 30.12%
2022 22.26 -7.86%
2021 24.16 6.69%
2020 22.65 -52.59%
2019 47.77 137.69%
2018 20.10 -85.80%
2017 141.54 -188.38%
2016 -160.15 194.95%
2015 -54.30 43.69%
2014 -37.79 0.67%
2013 -37.54 -54.76%
2012 -82.97 -136.06%
2011 230.08 -2,573.28%
2010 -9.30 -19.61%
2009 -11.57 24.62%
2008 -9.29 21.26%
2007 -7.66 -62.60%
2006 -20.48 68.70%
2005 -12.14 143.00%
2004 -5.00 23.34%
2003 -4.05 -63.36%
2002 -11.05 -60.02%
2001 -27.65 -77.34%
2000 -122.02 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -64.45%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -43.49%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 0.98%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 9.72%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 38.30 27.06%
NL
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.